<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905901</url>
  </required_header>
  <id_info>
    <org_study_id>17300595</org_study_id>
    <nct_id>NCT04905901</nct_id>
  </id_info>
  <brief_title>Nebulized Tranexamic Acid in Sinus Surgery</brief_title>
  <official_title>Does Nebulized Tranexamic Acid Affect Operative Field in Sinus Surgery? A Double Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of several recent studies on endoscopic sinus surgery through topical&#xD;
      administration of tranexamic acid are encouraging in terms of the efficacy of tranexamic acid&#xD;
      for intraoperative bleeding and other pathological conditions.The purpose of this study is to&#xD;
      analyze the efficacy of nebulized tranexamic acid to improve the surgeon and patient&#xD;
      experiences of sinus surgery and know the effective and safe dose of nebulized tranexamic&#xD;
      acid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent will be taken from the patients.The study involved adults of&#xD;
      either sexes (age 18-65 years) of ASA I-II who will be listed for elective functional&#xD;
      endoscopic sinus surgery (FESS) under general anesthesia, with normal accepted coagulation&#xD;
      profile and hematocrit value ≥30 %. Excluded from the study patients with chronic renal&#xD;
      failure, liver cirrhosis, bleeding disorders, current anticoagulant therapy, pregnancy or&#xD;
      breastfeeding, impaired color vision, severe vascular ischemia, history of venous thrombosis,&#xD;
      pulmonary embolism, long term treatment with acetylsalicylic acid or non-steroidal&#xD;
      anti-inflammatory drugs not discontinued before surgery, a hemoglobin (HB) concentration &lt;10&#xD;
      mg/dl or allergy to TXA.&#xD;
&#xD;
      Randomization: A random number sequence created by an internet website (http://www.&#xD;
      random.org) will be used for patients' allocation. The random number sequence was retained in&#xD;
      closed opaque envelopes released the day of the surgery by an independent physician not&#xD;
      involved in the study. Patients will be assigned randomly to three groups (30 subjects each);&#xD;
      saline placebo (Group S) and two different doses of preemptive nebulized tranexamic acid&#xD;
      (Group T1) and (Group T2).To keep blinding, Group S will receive 2 sessions of nebulization&#xD;
      each by 5 ml saline. Group T1 will receive one nebulization session 500 mg tranexamic acid (5&#xD;
      ml) and another one by 5 ml saline. Group T2 will receive 2 nebulization sessions each by 500&#xD;
      mg tranexamic acid (each by 5 ml)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Modena Bleeding Score (MBS) assessing surgical field</measure>
    <time_frame>After anesthesia induction to 60 minute</time_frame>
    <description>1= No bleeding, 2=Bleeding easily controlled by suctioning, washing or packing without any significant modification or slowing of surgical procedure, 3=Bleeding slowing surgical procedure, 4=Most of the maneuvers dedicated to bleeding control and 5=Bleeding that prevents every surgical procedure except those dedicated to bleeding control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HR</measure>
    <time_frame>Intraoperative duration</time_frame>
    <description>Heart rate beat/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MBP</measure>
    <time_frame>Intraoperative duration</time_frame>
    <description>Mean blood pressure mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthetic consumption</measure>
    <time_frame>Anesthesia duration</time_frame>
    <description>Extra doses of fentanyl and propofol and sevoflurane&gt;2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>After operation to 24 hour</time_frame>
    <description>Recording any adverse effects to TXA e.g.nausea, vomiting and any visual disturbances</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bleeding Nose</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized tranexamic acid 500 mg 15 minutes before operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid 1gm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized tranexamic acid 1 gm 15 minutes before operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline nebulization 15 minutes before operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Tranexamic acid nebulization 15 minutes before sinus surgery</description>
    <arm_group_label>Tranexamic acid 1gm</arm_group_label>
    <arm_group_label>Tranexamic acid 500 mg</arm_group_label>
    <other_name>Cyclokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Normal saline placebo nebulization 15 minutes before sinus surgery</description>
    <arm_group_label>Saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Either sexes (age 18-65 years) of ASA I-II who are listed for elective functional&#xD;
             endoscopic sinus surgery (FESS) under general anesthesia&#xD;
&#xD;
          -  normal accepted coagulation profile and hematocrit value ≥30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic renal failure&#xD;
&#xD;
          -  liver cirrhosis&#xD;
&#xD;
          -  bleeding disorders&#xD;
&#xD;
          -  current anticoagulant therapy&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  impaired color vision&#xD;
&#xD;
          -  severe vascular ischemia&#xD;
&#xD;
          -  history of venous thrombosis, pulmonary embolism&#xD;
&#xD;
          -  long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs&#xD;
             not discontinued before surgery&#xD;
&#xD;
          -  hemoglobin (HB) concentration &lt;10 mg/dl _allergy to TXA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assuit</name>
      <address>
        <city>Assiut</city>
        <state>Assuit</state>
        <zip>Assuit universi</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Soliman</last_name>
      <phone>01101266040</phone>
      <email>omarmakram347@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>Egypt Assuit university hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epistaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

